Wealth Enhancement Advisory Services LLC Acquires 1,556 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Enhancement Advisory Services LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 127,272 shares of the medical research company's stock after purchasing an additional 1,556 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Thermo Fisher Scientific were worth $66,211,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMO. Norges Bank purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $3,149,754,000. T. Rowe Price Investment Management Inc. boosted its holdings in Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after purchasing an additional 1,433,444 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after purchasing an additional 858,193 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after purchasing an additional 761,649 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $377,901,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,075 shares of company stock valued at $7,305,942. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $1.34 on Friday, reaching $402.41. The company had a trading volume of 2,521,302 shares, compared to its average volume of 1,879,798. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The stock has a market capitalization of $151.91 billion, a PE ratio of 24.34, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The firm's 50 day moving average price is $430.85 and its 200 day moving average price is $500.06. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the company posted $5.11 EPS. The business's revenue was up .2% on a year-over-year basis. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific's payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TMO. Argus decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Citigroup decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Scotiabank decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Finally, Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.